Background: Malignant potential of small (20 mm) nonfunctional pancreatic neuroendocrine tumors
Introduction
Pancreatic neuroendocrine neoplasms are rare and heterogeneous neoplasms with variable malignant potential. 1, 2 With the widespread use of cross-sectional imaging, asymptomatic nonfunctional pancreatic neuroendocrine tumors are now diagnosed with increasing frequency. 3 Surgical resection is the only potential cure for these tumors, and has long been advocated for all lesions. However, since pancreatic surgery carries a high risk of morbidity and mortality, [4] [5] [6] [7] the benefit/risk balance need to be carefully weighted. Small (2 cm) sporadic nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) have been suggested as good candidates for surveillance. [8] [9] [10] [11] However, all surgical series agree that about 10-15% of small NF-PNETs have malignant potential with lymph node metastasis on pathologic specimens or later recurrence. [12] [13] [14] [15] It is unclear how to preoperatively predict malignant behavior of small NF-PNETs and how to select patients for surgery or a surveillance strategy. The aim of this European multicentric study was to assess postoperative outcome and risk factors for recurrence of resected sporadic small (20 mm) NF-PNETs.
Methods

Inclusion criteria and data collection
Patients undergoing surgery between 1999 and 2014 were identified from pancreatic surgical databases of 16 European participating centers. Inclusion criterias were patients with (i) histopathologically proven pancreatic neuroendocrine tumors (PNET), (ii) nonfunctional tumor as defined by the ENETS guideline (nonfunctional status defined by the absence of a hormone hypersecretion syndrome 16 ), (iii) with largest diameter of 20 mm or below on preoperative cross-sectional imaging and (iv) completely resected (i.e. R0/R1) (by pancreas sparing or standard resection). Exclusion criterias were (i) recurrence of preoperatively resected PNET, (ii) PNET presenting with synchronous metastasis, (iii) PNET from proven genetic origin (Multiple Endocrine Neoplasia type 1, Von Hippel Lindau Disease), (iv) PNET with macroscopically incomplete (R2) resection and (v) duodenal/ampullary neuroendocrine tumors. Demographic, radiographic, pathologic, postoperative, and followup data were obtained from each center's databases with additional retrospective medical record review performed when necessary. Data were recorded in a preformatted data collection sheet. Minimum preoperative work-up included at least an abdominal computed tomography scan before surgery, magnetic resonance imaging, endoscopic ultrasonography and/or somatostatin receptor imaging, depending on the clinical situation and according to each attending discretion.
Postoperative course and follow-up
Postoperative mortality included all deaths occurring before hospital discharge or within 90-days. Morbidity included all complications following surgery until discharge and/or readmission, and was graded according to the Clavien-Dindo classification. 17 
Results
Patients and tumors characteristics
Overall, 210 patients fulfilling the inclusion criteria were eligible and included in the analyses. Patient characteristics are shown in Table 1 . Although all patients had presumed sporadic tumors, five patients (2.4%) had multiple lesions.
Surgical procedure and postoperative course Formal resection (pancreaticoduodenectomy or distal pancreatectomy) was performed in 121 patients and the remaining 89 underwent parenchyma-sparing surgery (enucleation or central pancreatectomy) ( Table 2 ). Major complication (Clavien-Dindo grade 3) occurred in 31 patients and the fistula rate was 40.5% (n = 85), including clinically relevant (grade B or C) in 16.7% (n = 35). The 90-day postoperative mortality rate was 0.5% (n = 1). Risk for postoperative pancreatic fistula was greatest in parenchyma-sparing surgery but no differences regarding mortality, overall complications, delayed gastric emptying, or postoperative hemorrhage were observed (Table 3) .
Tumor pathology
The median tumor size on pathological examination was 15 mm and significantly different (p = 0.04) from the one measure on preoperative imaging ( Table 2 ). The median size discrepancy compared to preoperative radiological evaluation was 2 (1) (2) (3) (4) (5) mm. In 6.1% (n = 13) of cases, the size of the tumors were more than 5 mm smaller in the pathological analysis, while 10.5% tumors (n = 22) were more than 5 mm larger in the pathological analysis compared to preoperative cross-sectional imaging. While the radiological measurement was 20 mm in all tumors, 9.6% (n = 20) of the tumors were larger than 20 mm in the pathological analysis. In almost two thirds of patients (62.9%; n = 132), lymph nodes were present and analyzed with the specimen. When present, a median of six nodes (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) were analyzed. In patients with lymphadenectomy, 10.2% (14 out of 132 patient with lymphadenectomy) had metastatic lymph nodes. The corresponding rates of metastatic lymph nodes were 23% (6 patients with metastatic lymph nodes/26 patients with harvested lymph nodes/27 patient total) for pancreaticoduodenectomy, 4% (3/69/94) for distal pancreatectomy, 31% (4/ 13/19) for central pancreatectomy, and 4% (1/24/70) enucleation. 3% (n = 4) of WHO 2010 grade 1, 16% (n = 6) of grade 2, and 100% (n = 1) of grade 3 tumors had metastatic lymph nodes. An R1 resection was considered to have been performed in 23 (11%) of tumors, all but three of these following parenchyma-sparing surgery.
Long-term outcome
After a median follow-up of 36 months (16-64), the median disease-free survival was not reached, and the 1-, 3-and 5-year disease-free survival rates were 96.4% (±1.3%), 93.5% (±1.9%), 93.5% (±1.9%), respectively (Fig. 1a) . Overall 5.9% (n = 11) of patients developed tumor recurrence at a median time of 8 (6-28) months. The most common site of recurrence was liver (n = 5), followed by lymph nodes (n = 2) and lung (n = 2). There was one local recurrence and one recurrence in multiple sites. Four of the 11 patients (36%) with recurrence underwent metastasectomy, of whom two (50%) remained free of disease during the follow-up. Disease-free survival was similar in patients who underwent pancreas-sparing pancreatectomy compared to formal resection (Fig. 2) .
The median overall survival was not reached, and the 1-, 3-and 5-year overall survival rates were 99.0% (±0.7%), 97.5% (±1.3%), and 96.2% (±1.8%) respectively. Only one patient, with a grade 3 tumor, died of metastatic PNET during follow-up. The cause of death was unrelated to PNET in three patients, and unknown in one patient.
Results of the univariate and multivariate Cox proportional hazards models are shown in Table 4 for both preoperative and postoperative parameters. Tumor size, and the presence of biliary or pancreatic duct dilatation on preoperative computed tomography (CT) were independent predictors of recurrence on Patients with positive lymph node on pathology 10.6% (14) WHO -World Health Organization. a On 157 patients with available data. multivariate analysis, Pathological tumor size and WHO 2010 grade were independent predictors of recurrence among parameters that were accessible postoperatively. All patients with 10 mm sized tumors (n = 59) were disease free at 1-, 3-and 5-year follow-up (Fig. 1b) . 10.2% (n = 5) of tumors below 10 mm in size presented with presence of biliary or pancreatic duct dilatation on preoperative CT. Patients with tumors sized 11-20 mm (n = 151) had worse disease-free survival rates at 1-, 3-and 5-year follow-up being 95.1% (±1.8%), 91.0% (±2.7%), and 87.3% (±4.4%), respectively (Fig. 1c) . Here, 7.9% (n = 12) of tumors between 11 and 20 mm in size presented with presence of biliary or pancreatic duct dilatation on preoperative CT.
For tumors over 20 mm in size on histopathology (n = 20), the 1-, 3-and 5-year disease-free survival rates were 77.8% (±9.8%), 71.8% (±10.7%), and 71.8% (±10.7%), respectively, and 35% of them (n = 7) presented with biliary or pancreatic duct dilatation on preoperative CT. Of tumors causing biliary or pancreatic duct dilatation (n = 23), 65% (n = 15) were WHO 2010 grade 1, 26% (n = 6) grade 2, 4% (n = 1) grade 3 (grade missing n = 1), and 17% (n = 4) had metastatic lymph nodes.
Behavior of tumors considered at low-risk of recurrence Seventy-one patients were considered as low-risk of recurrence based on the following criteria 11 : (i) 2 cm or smaller on preoperative imaging, (ii) no bile or pancreatic duct dilation, (iii) sporadic, (iv) asymptomatic, (v) no lymph node or distant metastasis in imaging studies, and (vi) WHO 2010 grade 1. The 1-, 3-and 5-year disease-free survival rates in this subgroup were 98.6% (±1.4%), 94% (±3.4%), 94% (±3.4%) respectively. One patient died of postoperative complications. Two patients developed disseminated disease, one in the lungs and the other one in liver at 31 and 51 months after surgery, respectively.
Discussion
If surgery used to be the cornerstone of the management of small NF-PNETs, this has been recently challenged. Indeed, in view of the severe and frequent complications of pancreatic surgery and the natural history of sporadic small NF-PNET 20 mm, expectant management has recently been proposed as a possible option.
In the present European multicentric study, including 210 patients with resected (20 mm) small NF-PNETs, several observations were made. First, about 7% of tumors presented with nodal metastasis at the time of resection (11% in patients in whom lymphadenectomy was performed). Second, overall 5-year disease-free survival was excellent (approximately 94%), and most importantly, none of the patients with tumors size below 10 mm recurred. Third, presence of biliary or pancreatic duct dilatation, size on preoperative CT, and WHO 2010 grade were independent predictors of recurrence. The presence of pancreatic duct involvement was identified recently also in another series as poor prognostic factor. 20 Fourth, parenchymasparing pancreatectomy carried the highest risk for pancreatic fistula, but was associated with long-term disease-free survival similar to formal resection in highly selected patients. If long-term disease-free survival after curative surgery is excellent, the results of non-operative management are of paramount interest. Two recent systematic reviews have explored the safety and feasibility of a non-operative management for asymptomatic small NF-P-NETs. 8, 21 While 22% of sporadic tumors showed growth during follow-up, only 12-14% required resection and no patients developed disseminated disease during the follow-up period. 8, 21 On the other hand, 52% of MEN1-related tumors showed growth, 25% underwent surgery and 9% developed disseminated disease, indicating that patients with MEN1-syndrome might need different strategy than patients with sporadic tumors. 8 Taken together, these results favor a wait- and-see policy in selected patients with asymptomatic small sporadic NF-PNET without bile or pancreatic duct obstruction. However, some patients with small NF-PNET most likely benefit from surgery. Several clinical or radiological preoperative factors have been identified earlier to predict poor prognosis of NF-PNET such as distant metastases, primary tumor size over 2 cm, WHO 2010 grade 2 or 3, or presence of radiological signs of node involvement. 9, 22, 23 But tumors below 2 cm in size remain poorly discriminant. Recently, genetic or transcriptomic markers have been investigated, 24, 25 but they are currently not clinically available, and their clinical relevance still needs to be confirmed. In the current study, larger size (even when below 2 cm), bile or pancreatic duct obstruction, and WHO grade 2-3 were identified as independent risk factors for poor disease-free survival even after surgery, suggesting that patients with growing tumor, presence of bile or pancreatic duct dilation, or suspicion/ confirmed WHO grade 2-3 are not good candidates for surveillance. Significant discrepancy between preoperative CT measurement and pathology size should also be noted. In the present experience, in about 10% of the cases in our study the tumor size was underestimated in the preoperative imaging. This discrepancy has been previously reported regarding pancreatic cancer tumors and cystic lesion size. 26, 27 While the correlation between tumor size and malignancy in NF-PNET is well demonstrated, 28 other parameters should also be taken into account. Falconi et al.
showed that nonincidental diagnosis of the tumor is an independent predictor of malignancy at multivariable analysis, 14,28 as well as KI-67 when preoperatively available on FNA. 29 Age obviously plays a role in selecting patients for surgery versus surveillance. Younger patients have lower risk of mortality after surgery and have longer surveillance ahead of them compared to old patients with possible comorbidities and shorter lifeexpectancy. Tumor location as well plays a role in selecting patients for surgery, and threshold for surgery might be lower in patients with body/tail lesion that do not require pancreaticoduodenoctemy. At the moment, there are no tools to predict whose tumor will grow, cause ductal dilation, or transform into WHO grade 2-3 tumor in the future. Thus, the dilemma in treating patients with small NF-PNET arises from the morbidity and mortality of pancreatic surgery -the only known curative treatment of these lesions. The mortality of pancreatic surgery varies between 1% and 3% in high-volume centers, 30, 31 but increases up to 6-10% when nationwide data is considered. 32, 33 Additionally, the morbidity of pancreatic surgery remains high. 34, 35 Furthermore, pancreatic fistula rates are higher in non-adenocarcinoma tumors, such as PNETs. 36 Overall, this indicates that the benefit-risk balance of pancreatic resection needs to be carefully weighted. In the present series from several European centers, early results of surgery are nevertheless favorable. The mortality rate is very low (0.5%). 40% of the patients underwent a parenchyma-sparing pancreatectomy, which were associated with higher risk of pancreatic fistula, but excellent long-term disease-free survival rates in highly selected patients. These points suggest that the patients were appropriately selected and that surgeons correctly estimated the risk-benefit balance of their procedure, excluding patients with high-operative risk and attempting to limit the functional consequences of surgery.
Whether to proceed with parenchyma-sparing or formal resection is a delicate decision, and in any case needs to be discussed with the patient and preferably made as a shared-decision. Parenchyma-sparing resections have higher morbidity, especially pancreatic fistula, but this morbidity does not transform into mortality in these patients. 37 On the other hand, parenchymasparing surgery yields in better long-term exocrine and endocrine function. 37 In the absence of high level evidence, current European or NCCN guidelines advocate operative strategy for symptomatic patients and tumors of over 2 cm in size, 38, 39 but suggest surveillance as an option in smaller sporadic asymptomatic lesions. This strategy is in line with this study's results and also supported by two recent systematic reviews demonstrating the safety of surveillance in selected patients. 8, 21 However, selecting patients for surgery versus surveillance needs to be carefully weighted, as demonstrated by two recent large registry based studies 13, 15 and a retrospective series 12 that have showed that small asymptomatic NF-PNETs have an unpredictable evolution and that a subset of them can behave malignant. While patient selection can be improved by recommending surgery for patients with bile/ pancreatic duct dilation or high KI-67, a few patients will remain having a malignantly behaving tumor. In our material, two out of 71 patients (3%), with tumors consistent with all signs of a benign lesion, developed disseminated disease after surgery. An RCT comparing upfront surgery to surveillance would provide higher level of evidence, but, due to the rarity of the tumors, is unlikely to be carried out in the near future. These observations also question the carcinogenesis of PNET. Whether a G1-G2 sequence exists as an adenoma-carcinoma sequence for pancreatic adenocarcinoma remain to be formally demonstrated. It is possible that the majority of PNET never become clinically relevant, and that the few patients who would progress can be identified during an initial observation. In this subgroup of patients, which may represent about 15% of small NF-PNET, it seems that delayed surgery would not compromise long-term outcomes. 11 However, earlier identification of progressive tumor would allow prophylactic surgery, and possible parenchyma sparing procedures. In this setting, systematic FNA could be helpful at least in order to rule out, G2 or high-G2 tumor, from a surveillance strategy. The strength of this study is the relatively large cohort stemming from several pancreatic surgery centers in the Europe, and thus providing better external validity than small single-center cohorts. Large number of patient allowed for multivariate analyses, and the detection of the role of pancreatic and bile duct obstruction on the prognosis of patients with small NF-PNET.
We are, of course, aware of some limitations of the present study. First, it is limited by its retrospective nature with inherited biases, such as the absence of standardized preoperative assessment. Second, we have data only on resected patients, and it is unknown how many patients have been under surveillance during the same time period in the participating centers. This would be of paramount interest, but unfortunately registries are kept for patients undergoing surgery only. Third, the reason why exactly these patients underwent surgery instead of surveillance is unknown, and might be surgeon and/or patient specific. Finally, the median follow-up in our series was just around 3 years, which might be too short to detect all recurrences. Further, there was a low proportion of G3 NF-PNETs in our cohort (n = 1). Most likely reasons for this are: (i) These tumors usually present with metastases, and metastatic tumors were excluded in our cohort. (ii) These tumors are rapidly growing and thus are often diagnosed beyond 2 cm, and again excluded from our cohort.
In conclusion, the postoperative and long-term outcome in small NF-PNET is excellent for the vast majority of patients. However, in sporadic small NF-PNET, presence of biliary or pancreatic duct dilatation on preoperative CT and WHO grade 2-3 are risk factors for aggressive tumor biology, and these patients, regardless of their tumor size, should undergo formal pancreatic resection with lymphadenectomy. The remaining patients are at low-risk of recurrence and a wait-and-see policy might be considered. As level 1 evidence is difficult, if not impossible, to obtain, other centers are encouraged to report their experience treating small NF-PNETs.
